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ABSTRACT 
 
 
This study was conducted during the period from 15/01/04 to 24 /04/04 at 
Sudan Fertility Care Association Center. 
Sixty nine Sudanese females using combined oral contraceptives were 
chosen for this study and twenty females not using contraceptives were 
used as controls. All individuals were within the same age group. 
Thyroid hormones; thyroxine (T4), triiodothyronine (T3), free thyroxine 
(FT4) and free triiodothyronine (FT3) were measured. In addition Thyroid 
stimulating hormone (TSH) was also measured in both groups. The study 
groups were divided according to the period of using combined oral 
contraceptives into four groups group1 (1–5) month, group2 (7–16) 
months and group3 (18–60) months and the control group of the non 
users. 
Determination of hormones concentrations were carried out using a 
highly sensitive specific Radioimmunoassay (RIA) technique  
The concentrations of serum T4 in group 3 was significantly higher 
(P<0.05) than in the control group while the level of T4 in group 1 and 2 
were found to be lower than in the control and the difference was not 
significant 
Mean serum concentration of triiodothyronine in the study group 1, 2 and 
3 were not significantly higher than the control group. 
Mean serum concentration of free triiodothyronine in the study groups 1, 
2 and 3 were not significantly higher than the control group.  
Mean serum concentration of free thyroxine in the study group 1, 2 and 3 
were not significantly higher than the control group. 
 Mean serum concentration of TSH in groups 1, 2 and 3 were 
significantly (P<0.05) lower than in the control group.  
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ﻓﻰ ﻫﺫﻩ ﺍﻟﺩﺭﺍﺴﻪ ﺘﻡ ﺍﻟﺤﺼﻭل ﻋﻠﻰ ﻋﻴﻨﺎﺕ ﺩﻡ ﻤﻥ ﺘﺴﻌﺔ ﻭ ﺴﺘﻴﻥ ﺍ ﻤﺭﺍﺓ ﺴﻭﺩﺍﻨﻴﺔ ﻴﺴﺘﻌﻤﻠﻥ ﺤﺒﻭﺏ 
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ﻟﻘﻴﺎﺱ ﻫﺫﻩ ﺍﻟﻬﺭﻤﻭﻨﺎﺕ ﺘﻡ ﺍﺴﺘﺨﺩﺍﻡ ﺍﻟﻁﺭﻴﻘﺔ ﺍﻟﻌﺎﻟﻴﺔ ﺍﻟﺤﺴﺎﺴﻴﺔ ﻭﺍﻟﺩﻗﺔ ﻭﻫـﻰ ﻁﺭﻴﻘـﺔ ﺍﻟﻤﻘﺎﻴـﺴﺔ 
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  ﺒﺼﻭﺭﺓ ﻤﻭﺜﺭﺓ  ﻜﺎﻥ ﺍﻋﻠﻰ ﺤﺒﻭﺏ ﻤﻨﻊ ﺍﻟﺤﻤل ﺍﻤﺎ ﻓﻰ ﺍﻟﻤﺠﻤﻭﻋﺔ ﺍﻟﺜﺎﻟﺜﺔ ﻓﻘﺩ 
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   ﻤﻭﺜﺭﺓ     ﻏﻴﺭ ﺘﻌﻤﻠﻥ ﺤﺒﻭﺏ ﻤﻨﻊ ﺍﻟﺤﻤل ﻭﺫﻟﻙ ﺒﺼﻭﺭﺓﺍﻟﻼﺘﻰ ﻻ ﻴﺴ
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INTRODUCTION 
 
Contraceptives are the only absolutely methods prevented unwanted 
pregnancy. They can be divided into mechanical, which includes condoms, 
diaphragms and intra-uterine devices (IUD), and chemical contraceptives, 
which include those taken internally and those applied externally. Oral 
contraceptives are biochemical compounds which contain sex hormones 
and can be divided into combined contraceptives which are mixture of a 
synthetic estrogen and progestin, the other type is containing only 
progestin and less effective than combined oral contraceptives, and their 
use is often restricted to women whose fertility is already reduced, such as 
older or lactating women (David, et al, 1993). Oral contraceptive pills as 
well as intra-uterine devices have been provided through a network of 
health care clinics and hospitals. Oral contraceptives are well known to 
affect the serum concentrations of endocrine parameters, which under 
normal conditions are not involved in the regulation of ovarian activity 
(Wiegratz, et al. 2003). 
Thyroid hormones and thyroxine-binding globulin are increased during 
hormonal treatment with oral contraceptives without changes in the 
thyroidal economy (Pansini, et al. 1987). 
It has been observed in a number of Sudan Atomic Energy laboratories 
that, a great number of healthy looking Sudanese women have abnormal 
thyroid function due to the use of oral contraceptives. The effect of oral 
contraceptives on the thyroid hormones status is not clearly known. A 
number of women are asked to perform thyroid function test while they 
are using oral contraceptives.  
The thyroid gland is located immediately below the larynx on either side 
of and anterior of the trachea, and secretes large amount of two hormones, 
  
thyroxine and triiodothyronine. Thyroid hormones are essential to many 
aspects of growth and the development of skeletal system, teeth, epidermis 
and central nervous system. To maintain normal metabolic rate in the 
body, precisely the right amount of thyroid hormones must be secreted all 
the time. To control the thyroid activity, a specific feed back mechanism 
operates through hypothalamus and anterior pituitary gland should be 
obtained all the time (Ganong, 1985). 
Objectives of the study  
The main objective of this study is to investigate the effect of oral 
contraceptive on the thyroid function in Sudanese women. 
Specific objectives 
- To determine thyroid related hormones in Sudanese female taking oral 
contraceptive.  
- To update the existing information concerning thyroid function during 
contraceptive usage. 
   - To know the effect of the duration of using the oral contraceptives on 
the thyroid function. 
  
 
  
 
 
 
 
 
 
 
  
 
 
 
CHAPTER ONE 
LITERATURE REVIEW 
 
1.1 The thyroid gland 
The thyroid is a butterfly shaped gland, which wraps around the front part 
of the windpipe just below Adam's apple. The thyroid is the largest single 
endocrine gland, its weighting 20-25g; and it varies with age, sex and 
physiological condition. It is the only endocrine gland that does not store 
its hormones with in the cell, but in follicular cavities surrounded by cells. 
It produces hormones that regulate metabolism and organ functions (Ernst, 
1965). 
1.1.1 Thyroid gland function 
The thyroid gland maintains the level of metabolism in the tissue that is 
optimum for their normal function. Thyroid hormones stimulate the oxygen 
consumption of most of the cells in the body, helps in regulation of lipid and 
carbohydrates metabolism, modulation of gonadotropin secretion by the 
pituitary, and maintenance of proliferative cell growth and maturation in 
hair. In addition thyroid hormones stimulate both the sodium pump and 
glycolytic pathways leading to calorigenesis and oxidative phosphorylation 
in tissues such as liver, kidney, and muscle (Halmi, 1978). In addition 
thyroid hormones regulate gene expression, tissue differentiation, and 
general development. The thyroid gland produces two hormones, 3,5,3 -
triiodothyronine (T3) and 3,5,3,5 tetraiodothyronine (T4, Thyroxine), which 
have long been recognized for their importance in regulating general 
  
metabolism (Robert and Murray, 1996).  
1.1.1.1 Synthesis of T3 and T4 
Iodide absorbed from the diet or drinking water is transported in the blood 
to the thyroid gland, where it is very efficiently transferred into the gland 
by an iodide pump system dependent on ATP. Uptake is inhibited by 
certain other ions such as perchlorate and thiocyanate, which compete for 
the transport sites. Once in the gland, the iodide ion is oxidized to free 
iodine, the reaction being catalyzed by peroxidase enzyme. The free iodine 
first iodinates position 3 of the tyrosyl groups of the protein thyroglobulin 
to form monoiodotyrosine (MIT) and subsequently iodinates position 5 to 
form diiodotyrosine (DIT). The process is spontaneous and no enzyme is 
required (Hywell. 1989). Thyroglobulin is glycosylated protein with a high 
molecular weight (660KD). It contains 115 tyrosine residues, each of 
which is a potential site of iodination. About 70% of the iodide in 
thyroglobulin exists in the inactive precursors, MIT and DIT can be 
coupled to form T4, T3. The iodotyrosines are also deiodonated in the 
thyroid gland by deiodonase enzymes. The free iodide is reutilized for 
thyroid hormone synthesis, a process known as the intrathyroidal iodine 
cycle, which is maximally utilized in situations of iodine deficiency (Ernst, 
1965). 
1.1.1.2 Secretion of T3and T4 
The right amount of thyroid hormones must be secreted at all times to 
maintain normal levels of metabolic activities in the body 
The thyroid hormones secretion is regulated by two general mechanisms 
including: 
1- Thyroid stimulating hormone (TSH) which increased proteolysis of 
thyroglobulin stored in the thyroid follicles with the resultant release of 
  
thyroid hormones, increased activity of the iodine pump, which increases 
the rates of iodine trapping in the glandular cell. Increase iodination and 
coupling (Guyton, 1991). 
2- The other way of thyroid hormones regulation is not TSH dependent and 
it's most important role is to modify the response to TSH probably by 
modifying the generation of (cAMP) consequent to TSH stimulation ( 
Wilson, 1992) 
 
1.1.1.3 Transport of T3 and T4 
Most of thyroid hormones in the plasma are associated with plasma proteins 
and less than 10% is free. These free hormones are in equilibrium with the 
bound form and are the part responsible for the tissue action of hormones. 
The amount of binding protein may be changed in various states e.g. 
increased in pregnancy, oral contraceptives, thus increasing the capacity to 
store thyroid hormone. If the concentrations of thyroid hormone per unit of 
binding protein remain constant the free thyroid hormone will not be 
changed. Measurement of total blood thyroid hormone (or of bound iodine) 
does not therefore reflect the thyroid status of the individual, such a system 
of transport means that the thyroid hormone supply to the tissue must be 
relatively constant. This fits with observations that replacement therapy is 
adequate if a constant level of thyroid hormone is maintained in plasma 
(Whithby, et al. 1994). Binding proteins are three: Thyroxine binding 
globulin (TBG), Thyroxine binding prealbumin (TBPA) and albumin. T4 
binds to all these in the pro-protein of 60, 30 and 10%. T3 binds rather 
weakly to TBG and albumin only. Free T3 and T4 are distributed throughout 
the extra-cellular space of the body where as the bound hormones are 
  
confined to the intravascular. This means that the greatest function of T3 is 
to be found in the extra-cellular space. The changes of thyroid function 
occur in the background of significant increase in renal iodine clearance. 
The impact of this increase in iodine clearance is especially significant in 
areas of borderline of low iodine intake (Lamb, 1981).   
1.1.2 Thyroid stimulating hormone (TSH) 
It is produced by basophil cell of anterior pituitary and is a glycoprotein in 
nature. Its molecular weight is approximatly 30.000 Kda. TSH consist of α 
and β- subunits. The α-subunit consists of 92amino acid residues while β-
subunit has 112 amino acid residues. Both α and β-subunits have several 
disulfide bridges. Its carbohydrate content is 21% and its β-chains bear two 
and one oligosaccharide chain linked by N-glycosidic linkages to specific 
asparagines residues. The chains are synthesized by separate structural 
genes and later undergo post-translation modification and glycosylation 
separately. The biologic half –life of human TSH is about 60 minutes TSH 
is degraded for the most part in the Kidney and to lesser extent in the liver. 
(Ganong, 1985).    
1.1.2.1 Thyroid stimulating hormone Function 
There are glycosylation receptors on the thyroid cell membrane which bind 
to the receptor binding site on β-subunit of TSH. The complex then 
activates adenylatecyclase which catalyzes the formation of cAMP which 
acts as the second messenger for most TSH actions as follows: 
1- The TSH stimulates the synthesis of hormones at all stages such as 
iodine uptake, organification and coupling.  
2- It enhances the release of stored thyroid hormones. 
3- It increases DNA content, RNA and translation of proteins, cell size. 
4- It stimulates glycoslysis, tricarboxylic acid cycle (TCA)  
5- It activates tissue lipase to enhance the release of fatty acids (lipolysis) 
(Martin, et al. 1995).   
  
1.1.2.2 Control of secretion 
TSH secretion is controlled by thyroid releasing hormone (TRH) secreted 
by hypothalamus. Somatostatin secreted by hypothalamus counteracts TRH 
and inhibits the release of TSH. When there is a high level of thyroidal 
hormones in blood, TSH level is decreased by inhibiting the releasing of 
TRH. (Chatterzea & Rona, 1993). An increase in total T3, total T4, free T3 
and free T4 concentration inhibit the secretion of TSH both directly and 
indirectly by inhibiting the secretion of thyroid releasing hormone (TRH) 
(Martin, et al. 1995).   
1.1.3 Iodine metabolism 
Iodine is a non-metallic element belonging to the halogen family. It is an 
essential trace element widely distributed in nature, and essential to the 
formation of thyroid hormones. 
Iodine content of food and water depends primarily on the supply of iodine 
in the soil.  
Dietary iodine is converted to iodide in the gut and absorbed in the small 
intestine. These are loosely bound with proteins and carried by the blood 
to the thyroid gland. 
The minimum daily iodine intake that will maintain normal thyroid 
function is 100-150µg in adults. The principal organs that take up the 
iodine are the thyroid, which uses it to make thyroid hormones, and the 
kidneys, which excrete it in the urine (Ganong, 1985).   
1.1.3.1 Iodide Trapping 
The thyroid concentrates iodide by actively transporting it from circulation 
to the colloid (iodide pump or iodide transport mechanism) The thyroid 
cell has a negative resting membrane potential, about 50 mv relative to the 
intestinal area and the colloid. Thus iodide is pumped into the cell against 
this electrical gradient and into the colloid, a very small amount of iodide 
also enters the thyroid by diffusion. 
  
Perchlorate and a number of other anions decrease iodide transport by 
competitive inhibition. The active transport mechanism is stimulated by 
TSH. It also depends on Na+/K+ ATPase and consequently is inhibited by 
ouabain. 
Iodide enters the thyroid follicular cell as inorganic iodide. It is first 
oxidized to a higher oxidation state (iodine) by the thyroid peroxidase. 
Then the oxidized iodide reacts with the tyrosyl residues in thyroglobulin 
to form diiodothyronine and monoiodothyronine, these compounds then 
combine to form T3 and T4 (Ganong, 1985).  
  1.1.4 Thyroid hormones binding protein 
1.1.4.1 Thyroid Hormone Transporter/TBG  
Thyroxine-binding globulin (TBG) is a glycoprotein produced in the liver 
that binds thyroxine with high affinity. Approximately 75 percent of the 
thyroxine in serum is bound to it; nearly all the rest is bound to 
transthyretin or albumin, so that less than 0.1 percent remains free or 
unbound. The physiological function of thyroxine-binding globulin is not 
known, but it may serve to distribute thyroxine evenly within tissues, 
particularly within large solid organs like the liver (Mendel, et al. 1987). 
This function is not critical, however, because patients with a complete 
absence of thyroxine-binding globulin, as a result of mutations in the gene 
for this glycoprotein, are clinically euthyroid and have normal serum 
concentrations of free thyroxine and thyrotropin concentrations, although 
their serum concentrations of thyroxine are low (Stockigt, 2001).  
Serum concentrations of thyroxine-binding globulin are similar in men 
and women, including postmenopausal women, indicating that its 
production is not affected by the different rates of estrogen production 
in normal men and younger and older women. The concentrations are 
high in pregnant women, patients with estrogen-secreting tumors, and 
women who are being treated with estrogen and oral contraceptives; 
  
this is because of an increase in the glycosylation of the protein, which 
slows its clearance, to a lesser extent, to an increase in its production 
(Ain, et al. 1987).                                                                                                                     
1.1.5 Metabolism of thyroid hormones 
The normal secretion from the thyroid gland contains approximately 80% 
thyroxine T4 and 20% triiodothyronine T3 the biological active form of 
thyroid hormone is T3 and it's derived from T4 (Brent, 1994). 
T4 and T3 are deiodinated in the liver, the kidneys, and many other tissues. 
One third of the circulating T4 is normally converted to T3 in adult 
humans, and 45% is converted to rT3. Thus, much more T3 and rT3 are 
formed by deiodination than are secreted by the thyroid. Two different 
enzymes are involved, 5 -deiodinase catalyzing the formation of T3 and 5¯-
deiodinase catalyzing the formation of rT3 
Because T3 acts more rapidly than T4 and is 3-5 times as potent on a molar 
basis, T4 is believed to be metabolically inert unit until it is converted to 
T3. Additional evidence in favor of this view is that T3 binds to nuclear 
receptors to a much greater extent than T4 (Ganong, 1985). 
In the liver, T4 and T3 are conjugated to form sulfates and glucuronides. 
These conjugates enter the bile and pass to intestine (Ganong, 1985). 
1.1.6 Effects of Thyroid Hormones  
Most of the widespread effects of thyroid hormones in the body are 
secondary to stimulation of O2 consumption (calorigenic action), although 
the hormones also affect growth and maturation in mammals, regulate 
lipid metabolism and increase the absorption of carbohydrate from the 
intestine. They also increase the dissociation of oxygen from hemoglobin 
by increasing red blood cell 2, 3-diphosphoglycerate (Ganong, 1985).  
  
 
1.1.6.1 Effect on Carbohydrate Metabolism 
Thyroid hormones increase the rate of absorption of carbohydrates from 
the gastrointestinal tract, therefore, the blood glucose level rises rapidly 
after a carbohydrate meal, sometimes exceeding the renal threshold 
(Ganong, 1985).  
1.1.6.2 Effect on Growth and Development 
Thyroid hormones are essential for normal growth, skeletal maturation and 
the development of the fetal and neonatal brain. In hypothyroid children, 
bone growth is slowed and epiphyseal closure is delayed. In absence of 
thyroid hormones, growth hormone secretion may also be depressed, and 
thyroid hormones potentiate the effect of growth hormone on the tissues 
(Ganong, 1985).  
1.1.6.3 Effects on skeletal muscle 
Muscle weakness occurs in most patients with hyperthyroidism, and when 
the hyperthyroidism is severe and prolonged myopathy may be severe. 
The muscle weakness may be due to increased protein catabolism. 
(Ganong, 1985). 
1.1.6.4 Effect on the Nervous System 
Both decreased and increased concentrations of thyroid hormones lead to 
alterations in mental state. With too little thyroid hormone the individual 
tend to feel mentally sluggish, while too much induces anxiety and 
nervousness. In hypothyroidism, mentation is slow and the CSF protein 
level will be elevated (Ganong, 1985). 
1.1.6. 5 Effect on Lipid metabolism 
Increased thyroid hormone levels stimulate fat mobilization, leading to 
increased concentrations of fatty acids in plasma. They also enhance 
oxidation of fatty acids in many tissues. Finally, plasma concentrations of 
cholesterol and triglycerides are inversely correlated with thyroid hormone 
  
levels - one diagnostic indication of hypothyroidism is increased blood 
cholesterol concentration (Brent, 1994). 
1.1.7 Thyroid gland disorders 
Disease is associated with both inadequate production and overproduction 
of thyroid hormones. Both types of disease are relatively common 
afflictions of man and animals.  
1.1.7.1 Hypothyroidism 
It occurs when there is an inadequate secretion of thyroid hormones, 
resulting in a slowing down of the body’s metabolism. (Morocco and 
Kloos., 2000). Hypothyrodism is the result of a deficiency of thyroid 
hormone activity? In children, it can cause a delay or a permanent deficit 
in growth and development (cretinism). In adults, hypothyroidism causes a 
number of signs and symptoms that are reversible with effective treatment: 
fatigue, depression, poor concentration, coldness and intolerance to cold 
environments, weight gain, constipation, fluid retention, muscle cramps, 
menstrual irregularities, hand numbness and carpal tunnel syndrome, joint 
pain (esp. shoulder), vertigo, hearing loss, lateral eye brow thinning, cool, 
dry, rough skin, coarse hair, brittle nails, hair loss, muscle weakness, low 
hear rate and cardiac output, hoarse voice, enlarged tongue. Most cases of 
hypothyroidism are readily treated by oral administration of synthetic 
thyroid hormone (Isselbacher, et al. 1994) 
1.1.7.2 Hyperthyroidism 
It results from excessive secretion of thyroid hormones. In most species, 
this condition is less common than hypothyroidism and is characterized 
by nervousness, weight loss, hyperphagia, heat intolerance, increased 
pulse pressure, a warm, soft skin, a basal metabolic rate from +10 to as 
high as +100.   In humans the most common form of hyperthyroidism is 
Graves's disease, an auto- immune disease in which autoantibodies bind 
  
to and activate the thyroid-stimulating hormone receptor, leading to 
continued stimulation of thyroid hormone synthesis. Another interesting, 
but rare cause of hyperthyroidism is so called thyrotoxicosis (Ganong, 
1985). 
1.1.7.3 Iodine deficiency 
Iodide is absolutely necessary for production of thyroid hormones; 
without adequate iodine intake below 10 µg/d, thyroid hormones cannot 
be synthesized. Secretion declines as a result of increased TSH secretion, 
hypertrophies, producing an iodine deficiency goiter that may become 
very large. Historically, this problem was seen particularly in areas with 
iodine-deficient soils, and frank iodine deficiency has been virtually 
eliminated by iodine supplementation of salt (Ganong, 1985). 
1.2 Contraceptives 
The only absolutely guaranteed, permanent contraception is castration. 
That means removal of the testicles or of the ovaries. Then fertilization is 
impossible. These can be divided into mechanical, which includes 
condoms, diaphragms and intra-uterine devices (IUD), and chemical 
contraceptives, which include those taken internally and those applied 
externally. Oral contraceptives is chemical contraceptives it is divided into 
combined oral contraceptives are mixture of a synthetic estrogen and 
progestin, the other type of oral contraceptives which containing only 
progestin are less effective than combined oral contraceptives, and their 
use is often restricted to women whose fertility is already reduced, such as 
older or lactating women (David, et al. 1993) 
1.2.1 Male contraception 
The development of reliable methods of hormonal contraception for men 
proved more difficult than women. The regulation of spermatogenesis is 
  
poorly understood, and the link between sexual activity and hormones is 
much more direct in men than in women. Any method that compromises 
the endocrine activity of the testes must also involve testosterone 
replacement if sexual function is to be maintained. The use of large 
amounts of testosterone to inhibit the secretion of follicle-stimulating 
hormone and luteinizing hormone and hence spermatogenesis is not new 
(Krester, 1976). 
1.2.2 Female oral contraceptives 
Combined oral contraceptives (COCs) which are taken orally, and act on 
the body's fertility by chemical means, known as pills, are most common 
form of pharmaceutical contraception, and prevention of unwanted 
pregnancy. They consist of a pill that women take daily. Most oral 
contraceptives now in widespread use are combinations of an estrogen and 
a progestin. Combined oral contraceptives are highly effective in 
preventing pregnancy about 5 women per 100 typical users and fewer than 
1 per 100 women with perfect use become pregnant per year ( Fu, et al. 
1999). 
1.2.3 Contraceptive formulation 
The first oral-contraceptive formulations marketed in the United States, in 
1960 and 1961, contained 2 to 5 times as much estrogen and 5 to 10 times as 
much progestin as the oral contraceptives now in use. The use of these high-
dose formulations was linked to increased risks of ischemic stroke, 
myocardial infarction, and pulmonary embolism in healthy young women. 
The doses of estrogen and progestin were reduced rapidly during the 1960s 
and 1970s because of concern about safety and because the reduction of the 
doses did not reduce the contraceptive effectiveness ( Ain, et al.1987). 
The reductions in the dose of estrogen are believed to have decreased the 
risk of venous thrombosis. Because the effects of combination oral 
contraceptives on cardiovascular risk factors such as lipid levels and glucose 
tolerance vary with the type of progestin used in conjunction with the same 
  
dose of estrogen, oral-contraceptive formulations with fewer adverse effects 
on these metabolic variables were developed ( Diana and Petitti, 2003). 
The combined estrogen–progestin oral contraceptives that are now on the 
market contain estrogen at doses ranging from 20 to 50 µg of ethinyl 
estradiol or, uncommonly, mestranol. These estrogens are combined with 
any of several different progestin, which may be given at the same dose 
every day ("monophasic") or at varying doses according to the phase of the 
cycle ("biphasic" or "triphasic") to mimic more closely the production of 
progesterone during the normal menstrual cycle( Diana and Petitti, 2003). 
1.2.4 Mechanism of action  
The primary mechanism of action of COCs is the inhibition of ovulation. 
The release of an egg, which commonly occurs in the middle of the 
menstrual cycle, is prevented by COCs. Two hormones produced by the 
pituitary, coordinate the development and release of an egg from the ovary 
progestin contained in COCs causes the cervical mucus to become thick 
and prevents sperm penetration. The sperm can not pass through the cervix 
and fertilization can not take place. Also COCS prevent fertilization by 
acceleration of ovum transport. FSH and LH both of these hormones 
ordinarily occur in the middle of a woman's menstrual cycle. The surge in 
LH is the trigger for ovulation. COCs inhibit the production of both FSH 
and LH and consequently prevent ovulation. In the very rare cases where 
ovulation may occur, another contraceptive mechanism of COCs acts to 
prevent fertilization (Hatcher, 1994).  
1.2.5 Intrauterine devices (IUDs) 
It is a type of contraceptives; the action of this method is to change the 
media of the uterus without hormonal change. IUDs, especially the now 
widely used copper containing IUDs (TCu-380Aand multiload). IUDs 
prevent sperm from reaching the uterine cavity and the fallopian tubes, 
where fertilization occurs. A foreign-body reaction in the uterine cavity to 
  
an IUD causes cellular and biochemical changes that may be toxic to 
sperm. Also, the copper in copper IUDs may be toxic to sperm (Sivin, et 
al. 1990). 
1.3 Effect of oral contraceptive on thyroid function 
1.3.1 Drugs affecting T4 and T3 transport in the blood circulation 
More than 99 percent of the T4 and T3 in serum are bound to one
 of the 
three major transport proteins: thyroxine-binding globulin (TBG), 
transthyretin, and albumin. Thyroid hormone-binding proteins bind 
approximately 70 percent of serum T4 and a larger fraction of serum T3; it
 is 
therefore the most important of the binding proteins. Although less than 0.1 
percent of T4 and T3 circulate unbound to proteins,
 it is the concentration of 
free hormone that determines the action of the hormones in tissues. 
Alterations in the serum concentrations of these binding proteins alter serum 
total T4
 and T3 concentrations, but not serum concentrations of free
 T4 and 
T3; therefore the patient remains euthyroid. Drugs may
 affect T4 and T3 
transport either by raising or lowering the serum concentration of a binding 
protein or by interfering with the binding of T4 and T3 to a binding protein. 
Nearly all the drugs that alter T4 and T3 transport do so by altering the 
serum concentration of TBG or its affinity for T4 and T3
 (Bartalena, 1990). 
1.3.2 Increases in Serum TBG Concentrations  
The most common causes of an increase in serum TBG concentrations are 
an increase in estrogen production and the administration of estrogen, 
either as a component of an oral contraceptive agent or as estrogen-
replacement therapy (Kuhl,et al. 1993). TBG is a glycoprotein that is 
synthesized in the liver. Estrogens produce increased sialylation of TBG, 
which decreases its rate of clearance and raises its serum concentration ( 
Bartalena and Robbins, 1992). The increase in TBG in serum is dose-
dependent. The usual doses of ethinyl estradiol (20 to 35 µg per day) and 
  
conjugated estrogen (0.625 mg per day) raise serum TBG concentrations 
by approximately 30 to 50 percent and serum T4 concentrations by 20 to 
35 percent ( Knopp, et al. 1985 ) .The increases begin within two weeks, 
and a new steady state is attained in four to eight weeks. In women with 
hypothyroidism who are receiving T4 and become pregnant, an increase of 
45 percent in the dose is needed, on average, to maintain normal serum 
TSH concentrations (Mandel, et al. 1990).  
Thus, the increase in serum total T4 concentrations induced by estrogen 
occurs as a result of at least a transient increase in T4 secretion.
 Addition of 
progesterone to estrogen therapy does not alter the estrogen-induced 
increase in the serum TBG concentrations, and progesterone alone has no 
effect. Oral estrogen has a first-pass effect on the liver; transdermal 
administration of estrogen does not raise serum TBG or T4 concentrations, 
even though serum estrogen concentrations are comparable to those 
measured after oral administration (Dhopesh,  et al. 1991).  
Serum TBG concentrations are increased in about 50 percent of patients 
who use heroin for long periods or are treated with methadone. Many of 
these patients also have abnormal liver function, so that the increase in 
serum TBG may result from liver disease rather than from specific effects 
of these drugs. Cocaine use has not been associated with changes in serum 
TBG, T4, or T3 concentrations (Dhopesh,  et al. 1991). 
Mitotane and fluorouracil are also associated with increases in serum 
concentrations of total T4 and T3, but serum free T4
 and TSH 
concentrations remain normal. It is likely that these drugs also increase the 
serum concentration of TBG (Van Seters, et al. 1991).  
Altered level of thyroxine binding protein can be caused by both acquired 
and hereditary causes. The most common cause of acquired TBG excess is 
a result of estrogen, either exogenous oral contraceptive or 
  
postmenopausal replacement) or the endogenous increase during normal 
pregnancy (Van Seters, et al. 1991).  
The mechanism for the estrogen mediated increase in TBG was originally 
explained due to increased TBG synthesis. However, recent studies have 
shown that the extent of sialyation of TBG directly influences the 
clearance from the serum and, therefore the circulating half-life. 
Desialyated TBG has a circulating half-life of only minutes whereas fully 
sialylated TBG has a circulating half-life as long as 3 days. Therefore, 
estrogens stimulate increased sialyation, which prolongs the circulating 
half-life, resulting in increased serum concentration (Glinoer, et al. 1990).          
Hereditary TBG defects are caused by mutation of the TBG gene, which 
are located on the X chromosome. The phenotype depending on the nature 
of the mutation can range from partial or complete TBG deficiency to 
excess TBG. Individuals with deficient TBG have reduced serum T4 and 
T3 concentration, but normal serum TSH concentration. Individual with 
excess TBG have elevated serum T4, T3 and TSH concentrations. Free T4 
and free T3 concentrations are normal in both TBG excess and deficiency. 
In addition to alter TBG concentration abnormalities T4, T3 binding also 
have been reported as a result of mutation in the tranthrien and albumin 
genes. Number of other acquired conditions and medications can alter 
serum levels of TBG. TBG is increased in acute hepatitis. The increase in 
circulating TBG results in a need for increased of thyroid hormone 
production to maintain normal or high normal of free T4 level (Glinoer, et 
al. 1990). Combined Oral contraceptives is associated with an increase in 
T4 and T3 that caused by an increase in the serum-binding capacity of 
TBG which reduces the clearance of respective hormones. On the other 
hand, an increased serum binding leads to a reduction of the free 
proportion of these hormones. Therefore, the resulting amount of Free T4 
  
and free T3 in the circulation as well as thyroid function may be 
unchanged during treatment with oral contraceptives (Wiegratz, et al. 
2003).  
In the women with normal thyroid function treated with estrogen, the 
serum free thyroxine and thyrotropin concentrations did not change, 
whereas, at 12 weeks the mean serum thyroxin and thyroxin- binding  
globulin concentrations had increased (Baha and Arafa, 2001). 
The effects of the oral contraceptive pill on the blood and urinary level, 
various hormones was studied using 5groups of women.Group1consisted 
of women using combined oral contraceptives pills for 1 to 12 years. 
Group 2 consisted of pregnant women during the first trimester. Group 3 
consisted of pregnant women during the second trimester. Group 4 
consisted of pregnant women during the third trimester. Group 5 consisted 
of nonpregnant women. The effect of contraceptives pills coincided with 
the effect of pregnancy during 3 rd trimester (Nasr, et al. 1982).     
  
CHAPTER TWO 
MATERIALS AND METHODS 
 
2.1 Subjects 
Eighty nine Sudanese females were employed in the present study all of 
them were visiting Sudan Fertility Care Association Center. Their ages 
range from 18-40 years. 
2.1.1 Study group 
Sixty nine using combined oral contraceptives were randomly selected. 
They were classified according to the duration of contraceptives use as 
follows: 
Group 1 (1 -5 months) 
Group 2 (7 -16 months) 
Group 3   (18-60 months) 
All subjects are married and have at least one child. They were examined 
by physician for the presence of thyroid enlargement, or other signs of 
thyroid disease.they were found to be normal and were not suffering from 
any endocrine disease. 
Other twenty Sudanese women using mechanical techniques to avoid 
pregnancy and never exposed to oral contraceptives were selected and 
used as control group all of them were apparently healthy and normal.   
2.2 Samples Collection  
Five ml of venous blood were collected in a dry tubes from all subjects 
(study and control  group).The blood was incubated at room temperature 
for about one hour to clot, then centrifuged at 2000 r.p.m for 5 minutes to 
separate serum from the cells, sera were stored at- 20Cº until analyzed.  
  
2.3 Radioactive reagents 
All radioimmunoassay reagents for the measurement of thyroid hormones 
and TSH were obtained from China, Institute for Atomic Energy (CIAE) 
Department of Isotopes (Beijing China). The reagents included tracer, 
standards, antibodies and separating agents for the different hormones. 
2.3.1 Radioimmunoassay (RIA) specific reagents 
Radio labeled antigen (tracer)    
1- I125 labeled T4 as solution in baritone buffer with bovine serum 
albumin (BSA) and 8anlinio-1-naphotalene sulphuric acid (ANS).         
2- I125 labelled T3 as solution in baritone buffer with bovine serum 
albumin and 8-anlinio-1-naphotalene sulphuric acid (ANS) . 
3- I125labeled F T4         
4- I125 labeled F T3 as solution in baritone buffer with (BSA) and ANS).    
      
Antibodies: 
1- T4 antibody suspension with antimicrobial agent (Sodium azid)      
2- T3 antibody suspension with antimicrobial agent (Sodium azid).   
3- FT4 antibody suspension with antimicrobial agent (Sodium azid)   
4- FT3 antibody suspension with antimicrobial agent (Sodium azid)          
Standards: 
1- Human serum Thyroxine with concentration (0, 20, 40, 80, 160, 240) ng 
⁄ml were used as standards  
2- Human serum Triiodothyronine with concentrations (0, 0.5, 1.0, 2.0, 
4.0, 8.0) ng ⁄ml. were used as standards            
3- Human serum Free Thyroxine with concentration (0, 0.47, 2.6, 8.6, 
30.34, 87.37) Pmol ⁄l were used as standards 
4- Human serum free triiodothyronine with concentrations (0, 1.06, 4.07, 
11.17, 35.55, 85.16) Pmol ⁄l were used as standards 
  
Separating agents 
Magnetic antibodies. 
2.3.2 Immunoradiometric assay (IRMA) specific reagents: 
Reagents for determination of TSH were obtained from China Institute for 
Atomic Energy (CIAE), Isotopes Department.  
The reagents include: 
 1.  labelled antibody (tracer) 
 I125- anti TSH (monoclonal) solution (red) in colour. 
 2. Standards 
Human serum TSH with the concentration 
(0.0, 0.3, 0.6, 3.0, 7.5, 15.0, 30.0, 60.0) mu ⁄l 
3.  Separating agents 
Magnetic TSH antibody (polyclonal suspension) 
4.   IRMA washing buffer 
TSH wash buffer (10.05 phosphate buffer 0.1pH value (7.4) and 10 BSH 
The methods used to measure serum total thyroid hormones (T4 and T3) 
were based on radioimmunoassay (RIA) techniques. While free thyroid 
hormones (F T4 and F T3) were measured by radioimmunoassay (RIA) 
using T4 analogue method which is now widely used in routine test 
(amerlax free T4 and free T3) RIA kits from china isotopes. And TSH 
measured using highly sensitive Immunoradiometric (IRMA) technique. 
2.4 Methods 
2.4.1 Determination of hormones by radioimmunoassay (RIA) 
techniques 
Principle of RIA: Antigen (Ag) and tracer (Ag*) compete with a limited 
amount of antibody Ab to form Ag-Ab or Ab- Ag* complexes. 
Ag + Ab + Ag* → Ab-Ag (complex) +Ag + Ag* → separation which 
achieved by solid phase and liquid phase. 
  
Supernatant containing Ag, Ag* and deposit containing (Ab-Ag +Ab- 
Ag*) All tubes were counted in a suitable gamma counter for 60 seconds. 
Generally the assay was carried out using tubes containing sample, 
standard, quality control (QC), non specific binding (NSB) (with no 
antibody) and total count tube which contains only tracer. 
 
2.4.1.1 Determination of total serum Thyroxine (T4) 
Tubes used in assay were labelled and arranged in assay rack,50µl were 
pipetted into the sample , standard and control labelled tubes respectively, 
500µl T4 tracer and 500µl antibody were added to all tube, one more tube 
without Ab added was used as NSB,  then all tubes were mixed thoroughly 
by a vortex mixer and incubated at 37C° for 45 minutes then the   test 
tubes rack was placed on magnetic separator  for 10 minutes, then the 
supernatant was decanted, tubes placed on absorbent paper  to drain for 5 
m, finally all tubes were counted with gamma counter for 60 seconds.  
2.4.1.2 Determination of total serum triiodothyronine (T3) 
Tubes used in assay were labelled and arranged in assay rack, 50µl were 
pipetted into the sample , standard and control labelled tubes respectively, 
500µl T3 tracer and 500µl T3 antibody were added to all tubes, one more 
tube without Ab added was used as NSB, then all tubes were mixed 
thoroughly by a vortex mixer and incubated at 37C° for 60 minutes, 200µl 
Precipitant was added in all tube after that  the tubes were centrifuged for 
20 minutes at 1500 r.p.m, , then the supernatant was decanted, tubes 
placed on absorbent paper  to drain for 5 m, finally all tubes were counted 
with gamma counter for 60 seconds.  
  
2.4.1.3 Determination of free thyroxin (free T4) 
Tubes used in assay were labelled and arranged in assay rack., 50µl were 
pipetted into the sample, standard and control labelled tubes respectively,   
200µl I125 T4 (tracer) and 200µl Anti T4 (antibody) were added to all tube, 
then all tubes were mixed thoroughly by a vortex mixer and incubated at 
37C° for 60 minutes, 200µl Precipitant was added in all tube after that  the 
tubes were centrifuged for 20 minutes at 1500 r.p.m, , then the supernatant 
was decanted. Tubes placed on absorbent paper to drain for 5 m, finally all 
tubes were counted with gamma counter for 60 seconds.  
2.4.1.4 Determination of free triiodothyronine (free T3) 
Tubes used in assay were labelled and arranged in assay rack., 50µl were 
pipetted into the sample, standard and control labelled tubes respectively,     
200µl I125 T3 (tracer) and 200µl Anti T3 (antibody) were added to all 
tube, then all tubes were mixed thoroughly by a vortex mixer and 
incubated at 37C° for 60 minutes. 200µl Precipitant was added in all tube. 
Tubes were then centrifuged for 20 minutes at 1500 r.p.m, then the 
supernatant was decanted, tubes placed on absorbent paper to drain for 5 
minutes, finally all tubes were counted with gamma counter for 60 
seconds.   
2.4.2 Principles of Immunoradiometric assay (IRMA) technique: 
Magnetic solid phase (Ab) was allowed to react with antigen (Ag) and 
then the complex formed was washed using buffer. Labelled antibody was 
then added to the medium to form a sandwich complex Ab-Ag-Ab*. After 
attaining equilibrium, the complex was washed twice to remove excess 
labelled antibody and read in gamma counter for 60 seconds. The 
concentration of Ag reacted with the antibodies is determined using 
standard of Ag. 
  
2.4.2.1 Determination of thyroid stimulating hormone (TSH).  
Tubes used in assay were labelled and arranged in assay rack, 200µl 
aliquot of standards, controls and sample were pipetted in to the labeled 
tubes, 50 µl I125anti TSH solutions was added and then the tubes were 
mixed thoroughly and incubated at 37Cº for 60 minutes, 500 µl antibody 
suspension were added, and mixed well. Tubes were mixed gently, free 
and bound fraction were separated using  magnetic separator , the 
supernatant was decanted, and then the precipitants were washed using 1.0 
ml washing buffer, the tubes were mixed and replaced on magnetic 
separator allowed to stand for 10 minutes. Supernatant was decanted and 
drained thoroughly on absorbent paper. Washing step was repeated and 
then the tubes were counted with gamma counter for 60 seconds. 
2.5 Radioactivity 
The significant feature of radioimmunoassay with reference to other 
immunoassays is the use of a radioisotopic label to discriminate between 
the antibody bound fraction and the free fraction of the antigen. A 
radioisotope is essentially an unstable atom which at sometime or other 
will disintegrate and emit sub-atomic particles or energy in the form of 
electromagnetic wave radiation. These particles or the energy can then be 
measured by an appropriate detection system.  
The disintegration of any single radioisotopic atom is random, and so it is 
not possible to predict a time when any given radioisotopic atom will 
disintegrate. Because radioactive disintegration is a chance event 
proportional to the total number of radioisotopes present, the number of 
radioisotopic emissions occurring at one time follows logarithmic decay 
curve.  
The ease of detection is certainly one of the most useful aspects of 
radioiodine labels. Iodine-125 is detected by placing the sample directly 
  
adjacent to crystal of sodium iodide, containing small amount of thallium. 
The gamma-rays from the radioisotope are absorbed by the crystal and the 
energy is then transmitted in the form of flashes of light. The photons in 
the crystal are counted by conventional photomultiplier tubes. To increase 
the efficiency of energy transfer from the isotope to the crystal, a small 
well is often made in the crystal in which the sample is placed.          
2.6 Apparatus and Allied materials 
1- Multi detector gamma counter NE 1612 from nuclear enterprises Ltd. 
Sight hill Edinburgh, UK 
2-.Refrigerated bench top centrifuge model Centra-7R, from International 
Equipment Company, 300 second Avenue, need hard high TS, AM, 
02194, USA 
 3- Tubes: polystyrene assay tubes code No.5001, round bottomed tubes 
with a capacity of 5ml and intermediate g.mm, from Allied Amersham 
International Ltd. Amersham, U.K. 
4-Pipettes (25-1000µl) and disposable tips from eppendorf Gmbt, 
Itamurage 65, Fed, Re p. Germany. 
5- Adjustable repeating syringe (50 µl - 2ml per shot) and comb tips from 
Eppendorf Gmbt, Itamurage 65, Fed, Re p .Germany. 
6- Vortex mixture, model G560-E from Scientific Industries Ink Bohemia 
N.Y11716, USA. 
7- Syringe, Germany5ml 0.7X30mm/22G X11A. 
8- Storage tubes 
9- Incubator 
 
 
Table. 1: Normal range of different hormones in humans 
 
                   
  
Normal range Hormone 
50 – 150 ng/ml T4 
0.8-3.0 ng/ml T3 
3.0-11.0 Pmol/l F T4 
0.8 –6.0 Pmol/l F T3 
0.4 - 4.0 µlU/L TSH 
 
Pmol/l→ Pico mol/liter 
  
2.7 Statistical Analysis 
This study is a case–control study to compare the concentration of thyroid 
related hormones in contraceptives users and non users. 
To perform this comparison t-test was done to see if there is any 
difference between the control and the study group. 
Further more the study group was divided into three groups according to 
the duration of using the contraceptives and to find if there is any 
difference between the groups one way ANOVA test was performed. 
  
                                                   CHAPTER THREE 
RESULTS 
3.1the effect of combined contraceptives on the serum concentrations 
of thyroid hormones and thyroid stimulating hormone  
Mean serum concentration of thyroxine in study and control groups were 
presented in table (2) and fig (1). The concentration in group3 is 
significantly (P< 0.05) higher than the control group, while in group 1 
and group 2 are non significantly lower than the control group.  
Mean serum concentration of triiodothyronine in study groups G1, G2 
and G3 are non significantly higher than the control group as presented in 
table (2) and fig (2). 
Mean serum concentration of free thyroxine is presented in table (2) and 
fig (3). The levels in the study groups G1, G2 and G3 are non 
significantly higher than the control group.  
Mean serum concentration of free triiodothyronine is presented in table 
(2) and fig (4). The levels in the study groups G1, G2 and G3 are non 
significantly higher than the control group.  
Mean serum concentration of thyroid stimulating hormone in study and 
control groups were presented in table (2) and fig (5). It was found that 
the concentrations in G1, G2 and G3 are significantly (P<0.05) lower 
than the control group.  
3.2 Comparison between groups 
One Way ANOVA test was performed to compare between the 
concentrations of T4, T3, F T4, F T3 and TSH of the three groups no 
significant difference was found (P>0.05). 
This is clear from the mean values in table (2). 
3.3 The effect of the duration of contraceptives on the serum 
concentration of thyroid hormones 
  
In group three which have long time of using contraceptives, there was an 
increase in the serum concentrations of T4 (11.8%), T3 (16%), FT4 
(3.2%) and FT3 (9.8%) compared with the control group also there was a 
decrease in the serum concentration of TSH (43.5%).        
 
Table. 2: Concentrations of thyroid and thyroid stimulating 
hormones of control and study groups.                                                
 
 
Groups 
 
Serum T4 
ng/ml 
Serum  T3 
ng/ml 
Serum F T4 
pmol/l 
Serum F T3 
pmol/l 
Serum TSH 
µlU/L 
 
No. of  
deliveries 
Control 
N=20 
102.8 ±19.5a 2.5 ±.48 a 9.2 ±3.4 a 3.1 ±0.59 a 2.3 ±1.7 a 4.0 ±1.8 a 
Group1 
N =23 
 
99.4 ±29 a 2.8 ±1.0 a 10.0 ±.4 a 3.3 ±0.5 a 1.4 ±0.6 b 3.3 ±1.5 a 
Group2 
N=23 
 
99.6 ±37 a 2.8 ±0.6 a 9.7 ±4.0 a 3.1 ±.59 a 1.4 ±0.7 b 3.2 ±1.6 a 
Group3 
N=23 
 
114.9 ±34 b 2.9 ±0.7 a 10.1 ±5.4 a 3.2 ±0.6 a 1.3 ±0.5 b 3.3 ±1.7 a 
Total of 
study 
group 
N=69 
 
104.6 ±34.4 b   2.8 ±0.8 a  9.9 ±4.6 a 3.2 ±0.6 a 1.3 ±0.64 b 3.2 ±1.6 a 
 
 
  
Means in the same columns having different letters from the control are significantly 
different (P< 0.05)  
 
 
Figure. 1. Effect of combined oral contraceptives on serum thyroxine 
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Figure.2: Effect of combined oral contraceptives on serum triiodothyronine 
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Figure.3. Effect of combined oral contraceptives on serum free thyroxine 
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Figure.4: Effect of combined oral contraceptives on serum free triiodothyromine 
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Figure.5: Effect of combined oral contraceptives on serum thyroid stimulating hormone 
 
 
 
 
 
0
0.5
1
1.5
2
2.5
3
3.5
4
4.5
control Group1 Group2 Group3
Groups
TS
H 
co
m
ce
nt
ra
tio
n 
u/
l
 
 
Group (1) 1-5 months 
Group (2) 6-17 months 
Group (3) 18-60 months 
 
  
 
 
 
 
 
 
 
 
 
Figure.6: Number of Deliveries 
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CHAPTER FOUR  
DISCUSSION  
 
The interrelationship between changes in serum thyroid hormone levels 
and the use of combined oral contraceptives has been studied extensively 
and carefully understood.  
Alterations of the levels of thyroid hormones and thyroid stimulating 
hormone, in women accompany combined contraceptives consumption are 
well known. (Nasr et al., (1982); Bartalena., et al (1990); Kuhl., et al 
(1993); Bartalena and Robbins., (1992); Mandel., et al (1990)). All 
workers suggested that estrogens used in combined oral contraceptives 
result in the increase of TBG concentration, which in turn increases the 
concentration of the plasma thyroid hormones. The effects of using 
combined oral contraceptives in the present study, were very clear 
especially in group (3) which is the group that used the pills for long 
period of (18 – 60months)  as significant (P< 0.05) increase of T4 level 
and significant (P< 0.05) decrease in TSH level.  
  
4.1 Serum total thyroxine changes in females using                         
combined oral contraceptives: 
Table (2) showed that the increase in total thyroxine T4 concentration in 
group 3 which was of 11.8% and significantly (P< 0.05) higher than the 
control this work, is similar to that reported by (Nasr, etal.1982), where he 
studied women used oral contraceptives for 1 to 12 years. This indicates 
that the effect of contraceptives on the thyroid gland appears after one 
year. How ever Baha and Arafa, (2002) reported a significant increase in 
the serum concentration of T4 in women using combined oral 
contraceptives for 6 weeks.  
The rise in the level of total T4 due to the combined oral contraceptives 
was suggested to be caused by an increase in the serum-binding capacity 
of thyroxine-binding globulin which reduces the clearance of this hormone 
(Wiegratz,  et al. 2003), but lower levels were reported   in G1 and G2 
which are within the normal range 
4.2 Serum total T3 changes in females using combined oral 
contraceptives 
Table (2) showed that there was increased in the level of T3 concentration 
in G1, G2 and reached 16% in G3 These results were similar to that 
reported by (Wiegratz, et al. 2003), Combined Oral contraceptives is 
associated with an increase in total (T3) that caused by an increase in the 
serum-binding capacity of thyroxine-binding globulin which reduces the 
clearance of this hormone.  
4.3 Serum free thyroid hormones FT3 and FT4 changes 
Fig (3) and (4) showed that the increase in F T3 and F T4 concentration in 
the three groups which could be due to pituitary stimulation of thyroid 
hormone secretion, because the thyroid stimulating hormone reported 
lower level in all women using combined oral contraceptives these 
  
findings was not agreed with (Baha and Arafa, 2002) an increased in 
serum binding protein reduced the clearance of T4 and T3 that leads to a 
reduction of the free proportion of these hormones. Also Wiegratz, et al. 
(2003), reported that the amount of FT4 and FT3 may be unchanged during 
treatment with combined oral contraceptives.Glinoer, et al (1990) reported 
that the increase in the circulating TBG, results in a need for increased 
hormones production to maintain normal or high normal level of free T4 
level. These coincide with higher levels of free T3 and free T4 reported in 
oral contraceptives users in the present work.  
4.4 Serum thyroid stimulating hormone changes in females using 
combined oral contraceptives: 
 Fig (5) showed that the decrease in TSH concentration in the three groups 
using combined oral contraceptives compared to the group not-using oral 
contraceptives that was due to the increase in total T3, total T4, free T3 and 
free T4 concentration inhibit the secretion of TSH both directly and 
indirectly by inhibiting the secretion of thyrotropin releasing hormone 
(TRH) (Martin, et al. 1995). Non significant higher levels of free T3 and 
free T4 in women using oral contraceptives in the present study might be 
the direct cause of decreased TSH levels in group (1, 2 and 3) compared to 
the control. Since, the most common cause of acquired TBG excess is 
estrogen either exogenous or endogenous (Ain, et al. 1987). The findings 
in the present work can be explained as that, the period of oral 
contraceptives consumption can influence the levels of the circulating 
TBG and the thyroid hormones together with the levels of the TSH, this 
effect was most clear in group three which used the contraceptives for 
longer period between (18 – 60 months) . In this group the differences 
were obvious and scored significant (P< 0.05) levels in the TSH and T4.    
 
  
 
  
CONCLUSIONS 
 
Some interesting findings were observed among the study group 
1- Significant changes in thyroxine and thyroid stimulating hormone 
appeared after 18 months of using combined oral contraceptives which 
means that the use of contraceptives for long time has an effect on the 
serum concentrations of thyroid related hormones.   
2-increase in thyroxine (T4) and triiodothyronine (T3) seems to be 
correlated with increase in the level of thyroid binding globulin (TBG) as a 
result of the oral contraceptives. 
3- Free thyroxine (FT4) and free triiodothyronine (FT3) were found to be 
increased not significant but independent on decrease thyroid stimulating 
hormone (TSH). 
4- Reduction of thyroid stimulating hormone due to increase in T4 and T3 
which can be explained with feedback inhibition mechanism. 
5- Further research is needed to determine other important parameters such 
as thyroxine binding globulin (TBG). 
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